IngredientsBridges' penstemon is botanically known as Penstemon rostriflorus Kellogg. The species was scientifically described and named in 1860 by Albert Kellogg, though it was usually identified as Penstemon bridgesii in older sources. The fact that Kellogg's name had priority was noticed by Frank Crosswhite and published in the 1984 fourth volume of the Intermountain Flora. The current accepted name is therefore Penstemon rostriflorus Kellogg (1860), with the following recognized synonyms:
The common name "bridge" honors a 19th-century plant collector who shipped a specimen of this striking wildflower to the great botanist Asa Gray in 1868. Gray named the plant for the collector, and Penstemon bridgesii remained the scientific name until a century later, when an even earlier description of the plant by botanist Albert Kellogg was discovered. The scientific name Kellogg had given the plant, P. rostriflorus, took precedence, though "bridge" persists as a common name.
Kellogg named it rostriflorus, meaning "beak flower" in Botanical Latin. The species epithet "rostriflorus" thus means "beaked flower."
The plant is known by the common names beak-flowered penstemon or beaked penstemon, beak-flowered beardtongue or beaked beardtongue. Like other red-flowered hummingbird-adapted penstemons it is called scarlet penstemon. Older names still used include bridge penstemon and Bridges' penstemon. Additional common names include Beaked Penstemon and Mountain Fountains.
It is classified in the genus Penstemon within the family Plantaginaceae. Penstemon is a large genus of roughly 280 species of flowering plants native to North America from northern Canada to Central America, and is the largest genus of flowering plants endemic to North America. Formerly placed in the family Scrophulariaceae by the Cronquist system, new genetic research has placed it in the vastly expanded family Plantaginaceae. The Penstemon genus is placed alongside others in tribe Cheloneae; prior to 2005 its members had usually been included in the figwort family, Scrophulariaceae.
The full APG IV classification is: Kingdom Plantae → Order Lamiales → Family Plantaginaceae → Tribe Cheloneae → Genus Penstemon → Species Penstemon rostriflorus Kellogg (1860).
The species has no recognized varieties, but has been described as a variety of one of its three synonyms.
Penstemon rostriflorus is an evergreen perennial herb or subshrub native to the chaparral and pine-oak woodlands of California and the Southwestern United States, particularly in areas with well-drained soils. It typically forms clumps of many erect stems from a woody base and can reach up to 1 meter (approximately 3 feet) in height. The plant resembles a small shrub and has stems that are woody near the base with many leaves. The stems can reach 24 to 100 centimeters, but usually are taller than 30 cm. The stems can be hairless or vaguely hairy, with some plants hairless near the base and covered in glandular hairs toward the ends.
The leaves are linear to lance-shaped, smooth-edged, and up to 7 centimeters long. The showy inflorescence bears tubular red to orange-red flowers 2 to 3 centimeters long, with a distinctive hooded upper lip and a three-lobed lower lip, blooming from late spring to early summer.
This subshrub penstemon is also much longer-lived than most other beardtongue species. Plants have survived up to 20 years in botanic gardens, unusual in a group of plants known as short-lived perennials that may persist for only two to three years.
The flowers are usually large and showy, tubular, and bilaterally symmetrical, and have four fertile stamens and one sterile stamen (staminode). The prominent, often hairy staminode is the most distinctive anatomical feature of the genus as a whole.
Penstemon rostriflorus grows in shady canyons or dry, mountain slopes with Gambel's oak, Ponderosa pine, sagebrush, or pinyon-juniper vegetation. It ranges from the Sierra Nevada of eastern California to southern Utah, Colorado, and south to northern Arizona and New Mexico. Native habitat includes dry slopes in pinyon and ponderosa pine forests at elevations of 4,500 to 10,000 feet.
As an ingredient in botanical or nutritional products, Bridges' penstemon appears principally in the following forms, based on documented traditional and modern use contexts:
Historically, various Native American tribes valued Penstemon species for their medicinal properties, and while records specifically detailing Bridges' penstemon are sparse, it is often grouped with other Penstemon varieties in ethnobotanical literature. The genus as a whole has a well-documented history of indigenous medicinal application. Several Penstemon species were widely used in the past by Native Americans as medicinal plants with many various applications, such as pain relieving (e.g., Penstemon acuminatus), laxative (Penstemon confertus), wound healing (Penstemon deustus), or anti-inflammatory (Penstemon fruticosus var.).
Historical ethnobotanical records, such as those compiled by Daniel Moerman and documented in various regional ethnographies, note its application as a poultice or wash for wounds. However, these uses are based on oral tradition and the practical knowledge of indigenous healers rather than formal scientific investigation.
Wound care and dermatological use: Traditional uses included remedies for minor wounds, burns, and skin irritations, where crushed leaves or poultices were applied topically to promote healing and reduce inflammation. The Indians of the southwest, including the Chumash, and probably the Kumeeyay, used local penstemons externally for their wound-healing properties. They would make a poultice of the leaves and flowers to apply to sores, wounds, insect bites, and other skin problems.
Respiratory use: Some communities used infusions or teas made from Penstemon to soothe sore throats, coughs, and chest congestion, leveraging the plant's perceived mild expectorant qualities.
Psychological / emotional use: Celia Garcia, a Chumash medicine woman, reported that penstemon was also used for grief issues, although she did not indicate how it was used.
Other reported genus-level ethnobotanical uses: The Karuk used blue penstemon (Penstemon cyaneus) to treat depression. Different southwestern and intermountain peoples used various Penstemon species as analgesics, laxatives, and topical anti-inflammatories. The leaves and roots of related species such as Penstemon gentianoides were used therapeutically for inflammation-related conditions from Aztec times.
These uses are based on oral tradition and the practical knowledge of indigenous healers rather than formal scientific investigation. While records specifically detailing Bridges' penstemon are sparse, it is often grouped with other Penstemon varieties in ethnobotanical literature. Ethnobotanical accounts for this particular species are largely inferential, drawn from documentation of closely related taxa and general records for the wider genus.
No species-specific phytochemical analysis of Penstemon rostriflorus has been identified in peer-reviewed literature at the time of this writing. The chemical constituency of Bridges' penstemon must therefore be inferred from systematic analyses of closely related Penstemon species. Iridoid monoterpenes, flavonoids, and phenylpropanoids are present in Penstemon species and may all contribute to observed anti-inflammatory activity.
Iridoid glycosides are among the most well-characterized and taxonomically consistent chemical classes across the Penstemon genus. The genus is rather homogeneous with regard to the distribution of iridoid glucosides; aucubin and/or catalpol, as well as 6-O-esters of catalpol, are universally present in 10 of the 12 subgenera for which data exist.
Specific iridoid glycosides identified across multiple Penstemon species include:
Two varieties of Penstemon rydbergii were found to contain the iridoid glycosides euphroside, aucubin, geniposidic acid, and plantarenaloside, together with the phenylpropanoid glycoside verbascoside.
Verbascoside (acteoside) is a key phenylethanoid glycoside frequently identified in Penstemon species. Verbascoside, also known as acteoside, is a phenylethanoid glycoside frequently found in different plants, whose use in traditional medicine has been reported and experimentally supported. In Penstemon, it has been documented in P. gentianoides and P. campanulatus.
Other phenylpropanoid glycosides identified across the genus include martynoside and, from Penstemon crandallii, the new phenylethanoid glycosides 2-O-acetyl-3'''-O-methylverbascoside and 2,4''-di-O-acetyl-3'''-O-methylverbascoside.
Known compounds in Penstemon campanulatus include three iridoid glucosides, one phenylpropanoid glucoside, one monoterpene glucoside, one monoterpene lactone, and three flavonoids. The specific flavonoids most frequently identified in the genus are:
Additionally, phenolic acids as well as fatty acids have been determined through GC-MS analysis of Penstemon campanulatus. The broader penstemon genus also contains glycosides and alkaloids that are associated with wound-healing properties and are also described as anti-inflammatory, antimicrobial, and antiviral. However, this last claim is not yet supported by species-specific studies on P. rostriflorus.
All proposed mechanisms described below are based on research conducted on other Penstemon species or on the isolated compounds found across the genus. No species-specific mechanistic research has been published on Penstemon rostriflorus itself.
Iridoid monoterpenes, flavonoids, and phenylpropanoids present in Penstemon species may all contribute to the observed anti-inflammatory activity. At the molecular level, verbascoside has been specifically characterized: verbascoside has antioxidant activity and decreases NOS activities and reduces NF-κβ activation and nuclear translocation, and thus may modulate inflammatory reactions.
Research on Penstemon gentianoides demonstrated that extracts and isolated compounds inhibited the production of proinflammatory mediators: in one study, methanol, n-hexane, CHâ‚‚Clâ‚‚, ethyl acetate, and methanol/water (6:4) extracts, along with luteolin, diosmetin, verbascoside, martynoside, pensteminoside, globularisicin, and plantarenaloside isolated from P. gentianoides, were evaluated by determining their inhibitory effects on the production of proinflammatory mediators in lipopolysaccharide-activated macrophage cells.
The iridoid class broadly shows multiple mechanisms: more extensive studies have revealed that iridoids exhibit a wide range of bioactivity, such as neuroprotective, anti-inflammatory and immunomodulatory, hepatoprotective, and cardioprotective effects. Anticancer, antioxidant, antimicrobial, hypoglycemic, hypolipidemic, choleretic, antispasmodic, and purgative properties were also reported.
Extracts of Penstemon species, as well as their purified compounds, inhibited oxidation of β-carotene and crocin. These findings showed that iridoid monoterpenes, flavonoids, and phenylpropanoids present in these species may all contribute to the observed anti-inflammatory activity. Additionally, the observed antioxidant activity is correlated with the anti-inflammatory activity of these plants and the phytochemicals derived from them.
In studies of Penstemon campanulatus, all isolated compounds and the crude extracts were assayed for their antimicrobial activities against six Gram-positive and Gram-negative bacteria, as well as against three human pathogenic fungi. The traditional attribution of astringent or antimicrobial properties to P. rostriflorus specifically is noted in ethnobotanical records, but these properties have not been rigorously analyzed or quantified in modern phytochemical studies for this species.
Modern scientific research on Bridges' penstemon is still in its early stages. There are currently no large-scale, peer-reviewed clinical trials specifically focusing on this species. All experimental pharmacological evidence reviewed below derives from studies on other Penstemon species, primarily P. gentianoides and P. campanulatus. Extrapolation of these findings to P. rostriflorus is scientifically speculative in the absence of direct evidence.
Evidence type: Preclinical (animal and cell-based models only; no human data for the species or genus).
The most substantive pharmacological study on the Penstemon genus in relation to anti-inflammatory activity comes from a published study (PubMed-indexed) on P. gentianoides and P. campanulatus. The anti-inflammatory activities of MeOH, CH₂Cl₂, and ethyl acetate extracts and iridoid, flavonoid, and phenylpropanoid fractions from Penstemon gentianoides and P. campanulatus were studied in the TPA-induced mouse ear edema model. In addition, antioxidant activity against DPPH, crocin, and β-carotene were investigated.
All extracts were tested, and a selection of known compounds significantly (p < 0.05) inhibited mouse ear edema. The results showed that CHâ‚‚Clâ‚‚ extracts of roots and stems from P. gentianoides and ethyl acetate extracts of leaves from P. gentianoides and P. campanulatus, as well as luteolin, diosmetin, penstemide, and verbascoside, produced the most positive results. Of all substances tested, the CHâ‚‚Clâ‚‚ extract of P. gentianoides roots was the most powerful inhibitor (EDâ‚…â‚€ = 0.07 mg/ear), with activity comparable to that of indomethacin.
Limitations: These results are restricted to a murine (mouse) topical ear edema model, which is an in vivo animal model and not a human clinical study. No human clinical trials on anti-inflammatory effects of any Penstemon species have been identified in the peer-reviewed literature. The study species (P. gentianoides and P. campanulatus) are distinct from P. rostriflorus, and results cannot be directly applied to Bridges' penstemon without species-specific studies.
Evidence type: Traditional/ethnobotanical only; no clinical or preclinical experimental data specific to the species.
There is currently no scientific research or clinical trials validating the efficacy or safety of Bridges' penstemon for treating cuts or promoting wound healing. The traditional attribution of wound-healing properties rests on ethnobotanical records, not experimental verification. The traditional use is typically attributed to its potential astringent or antimicrobial properties, but these properties have not been rigorously analyzed or quantified in modern phytochemical studies.
Evidence type: Traditional/ethnobotanical only.
Penstemon plants, particularly some species like Penstemon digitalis, have been traditionally used for their potential respiratory benefits. The leaves of these plants have been employed to make herbal remedies that may help soothe coughs and respiratory irritations. No clinical or preclinical experimental evidence for respiratory effects of P. rostriflorus specifically has been identified.
Evidence type: Preclinical in vitro; no human data.
In vitro antioxidant studies have been conducted on multiple Penstemon species. Extracts from Penstemon species and compounds purified from them inhibited oxidation of β-carotene and crocin. These assays are standard in vitro screening methods and do not constitute evidence of antioxidant benefit in humans.
Evidence type: In vitro (cell/culture-based) only.
In the only existing reference at the time of publication, the anti-inflammatory activity of P. gentianoides and P. campanulatus extracts was reported. Subsequent research describes the isolation and structural elucidation of compounds of P. campanulatus together with evaluation of their antimicrobial activity against a panel of selected human pathogenic bacteria and fungi. No equivalent study has been performed on P. rostriflorus.
In summary, while definitive health effects of Bridges' penstemon in humans are yet to be established, its inclusion in nutritional products is supported by a growing interest in botanical diversity and traditional plants. More rigorous scientific studies — including clinical trials — are required to substantiate its efficacy and safety for specific health outcomes.
Based on the combination of traditional use records and genus-level preclinical pharmacological data, the following body systems and health areas are associated with Bridges' penstemon and related Penstemon species. All associations with claimed biological activity are derived from preclinical models or traditional use; none have been validated in controlled human trials for P. rostriflorus.
No standardized dosage guidelines have been established for Penstemon rostriflorus by any regulatory body or pharmacopeial authority (NIH Office of Dietary Supplements, WHO, EMA, ESCOP, USP, or European Pharmacopoeia). The species is not covered by any official monograph.
In the context of published experimental research on related Penstemon species, the following dosing information appears in preclinical studies:
No dosage information for human oral supplementation with P. rostriflorus preparations has appeared in peer-reviewed literature. While historical documentation of its uses is limited, anecdotal evidence suggests it was valued for its purported soothing and restorative properties and was sometimes incorporated into infusions for general health support. Specific preparation concentrations or volumes are not documented in recoverable ethnobotanical records for this species.
There is currently no scientific research or clinical trials validating the efficacy or safety of Bridges' penstemon for any specific use. No formal toxicological studies — including subacute, chronic, genotoxicity, or reproductive toxicity studies — have been published for Penstemon rostriflorus in peer-reviewed literature accessible through PubMed, PMC, or major botanical databases.
Based on broader botanical context, some safety considerations for the Penstemon genus warrant attention:
No peer-reviewed data on pharmacokinetic or pharmacodynamic interactions between Penstemon rostriflorus preparations and pharmaceutical agents have been identified. The presence of verbascoside (acteoside) across the genus is noteworthy because, at the compound level, verbascoside reduces NF-κβ activation and nuclear translocation, and thus may modulate inflammatory reactions. Theoretical interactions with immunosuppressant or anti-inflammatory medications based on these mechanisms remain speculative and unverified in clinical settings for any Penstemon species.
Bridges' penstemon (Penstemon rostriflorus) does not appear in any official pharmacopeial monograph (WHO, ESCOP, German Commission E, USP, European Pharmacopoeia) as of the time of this writing. It has no regulatory status as an approved drug or authorized herbal medicinal product in the United States, European Union, or any other major jurisdiction found in available regulatory databases. Its use in dietary supplements falls under the general provisions governing botanical ingredients, without any specific health claim authorization.
Health conditions that Bridges penstemon may help support.
Body systems that Bridges penstemon may help support.
Go back